Inderjit Kaul reports a stock award at Minerva Neurosciences
By AlphaYouPublished Form 4
Kaul Inderjit
Reporting filer
Inderjit Kaul reports a stock award, not an open-market purchase or sale, in Minerva Neurosciences, Inc.. Form 4 filed Nov 3, 2026 lists 1 entry.
- Disclosed
- Nov 3, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) (derivative) | Kaul Inderjit | 2026-11-02 | A | Grant or award | 2328 | 0 | 2,328 | 1 day | Filed terms
|
Stock Option (right to buy) (derivative)
- Owner
- Kaul Inderjit
- Date
- 2026-11-02
- Code
- A
- Action
- Grant or award
- Quantity
- 2328
- Price
- 0
- Following holdings
- 2,328
- Reporting delay
- 1 day
- Filed terms and references
Filed terms
- security Title: Stock Option (right to buy)
- conversion Or Exercise Price: 2.345
- transaction Date: 2026-11-02
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- transaction Shares: 2328
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- id: F1
- expiration Date: 2036-11-02
- underlying Security Title: Common Stock
- underlying Security Shares: 2328
- shares Owned Following Transaction: 2328
- direct Or Indirect Ownership: D
- nature Of Ownership:
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Kaul Inderjit: Director.
- F1: 25% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.
Original sources
Prepared automatically from public filing data. Report a correction.